# Andreas Lindblom

> Andreas Lindblom is a venture - series unknown investor at EIC backing Health Care and Medical. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [EIC](https://shizune.co/investors/profile/eban)
- Location: Stockholm, Sweden
- Total investments: 13
- Last investment: Mar 2026
- Lead investor: 92%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/mrandreaslindblom/

Andreas Lindblom is a venture - series unknown investor at EIC in Stockholm focused on Health Care and Medical. Former CEO at Spring Securities, co-founder of Karolinska Center for Advanced Medical Simulation and Training, group manager at Sales & Service at Itivity, and physiotherapist at the Karolinska Institute. Andreas holds degrees in physics and physiotherapy.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 38% |
| Medical | 3 | 23% |
| Biotechnology | 3 | 23% |
| Genetics | 2 | 15% |
| Pharmaceutical | 2 | 15% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 5 | 38% |
| Series A | 2 | 15% |
| Series B | 1 | 8% |
| Equity Crowdfunding | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Everdrone | Everdrone is at the forefront of a new era in public safety, where emergency drones are a critical and integrated part of everyday life. Our drones provide critical support to emergency response organisations by reaching incident scenes faster than any ground unit to gather vital information and deliver life-saving medical equipment. | $3.9M | Venture - Series Unknown | Mar 19, 2026 |  |
| NEOGAP Therapeutics | NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. | $9.8M | Venture - Series Unknown | Feb 11, 2026 |  |
| TIRmed Pharma | TIRmed Pharma develops drug candidates addressing major clinical needs. | $4.7M | Venture - Series Unknown | Apr 09, 2025 |  |
| PeptiSystems | PeptiSystems focuses on manufacturing and supplying instruments for the solid-phase synthesis of peptide and oligonucleotide therapeutics. | $4.1M | Venture - Series Unknown | Dec 20, 2024 |  |
| Capitainer | Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. | $1.4M | Series A | Feb 15, 2024 |  |
| NEOGAP Therapeutics | NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. | $4.9M | Venture - Series Unknown | Nov 09, 2023 |  |
| NEOGAP Therapeutics | NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. | $4.9M | Venture - Series Unknown | Nov 09, 2023 |  |
| Capitainer | Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. | $5.8M | Series A | Apr 24, 2023 |  |
| Encare | Encare was established in 2009 to implement the ERAS Protocols on a global basis by- providing training to health care professionals on the ERAS Protocols- providing an interactive and web-based information system for evidence based - best practice management (EBM)The company has developed an interactive, user-friendly interface forthe collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence.The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings.Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States.The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery. | $2.4M | Venture - Series Unknown | Sep 19, 2022 |  |
| Capitainer | Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. | $3.5M | Series B | May 31, 2022 |  |

10 of 13 investments shown.

## Co-investors
- [Sciety Venture Partners](https://shizune.co/investors/profile/sciety-venture-partners) — VC Fund, 4 deals together
- [Hadean Ventures](https://shizune.co/investors/profile/hadean-ventures) — VC Fund, 1 deal together
- [Sciety](https://shizune.co/investors/profile/sciety) — VC Fund, 1 deal together
- [Segulah Medical Acceleration](https://shizune.co/investors/profile/segulah-medical-acceleration) — VC Fund, 1 deal together
- [We Venture Capital](https://shizune.co/investors/profile/we-venture-capital) — VC Fund, 1 deal together

## About EIC

VC Fund

European Innovation Council

5 contacts available at EIC.

| Name | Title | Profile |
| --- | --- | --- |
| Ana Barjasic | Board Member | https://shizune.co/investors/profile/ana-barjasic |
| Andreas Lindblom | EBAN Health Steering Committee | https://shizune.co/investors/profile/andreas-lindblom |
| Brigitte Baumann | President Emeritus | https://shizune.co/investors/profile/brigitte-baumann |
| Candace Johnson | President | https://shizune.co/investors/profile/candace-johnson |
| Francoise Birnholz | Affiliate Member | https://shizune.co/investors/profile/francoise-birnholz |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Andreas Lindblom invest in?

Andreas Lindblom invests primarily in Health Care, Medical and Biotechnology startups, most often at Venture - Series Unknown and Series A stage. Most of the 13 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andreas Lindblom last invest?

The most recent investment recorded for Andreas Lindblom closed in Mar 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co